Second Consecutive Quarter of Revenue
Growth; Each Business Reports Top-Line Improvement
Initiatives Focused on Reducing Complexity,
Driving Operational Excellence and Accelerating Growth Continue to
Move RTI toward Sustainable Long-Term Profitability
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical
implant company, reported operating results for the second quarter
of 2017. RTI has delivered two consecutive quarters of revenue
growth as its initiatives to transform the business continue to
yield improving operating performance.
In the second quarter 2017, as described in greater detail
below, each of RTI’s businesses generated top-line growth,
including its commercial business, which continues to show signs of
stabilization. RTI also delivered double-digit revenue growth
across its direct business, including its spine, surgical
specialties and cardiothoracic segments, as well as continued
revenue growth in its sports medicine and orthopedics segment and
its International business.
“We are making tangible progress toward our plan to transform
RTI and return it to a path of solid, predictable and sustainable
growth,” said Camille Farhat, chief executive officer, RTI. “While
we are still in the early phase of this effort and there is more
work to do, we are beginning to accomplish what we set out to
achieve. Our Commercial business continues to stabilize, our direct
business delivered another quarter of strong performance and our
Spine business continues to grow at above-market rates. We are
encouraged by our strong second quarter results and remain
laser-focused on implementing our strategic initiatives and
generating value for our employees, customers and
shareholders.”
As previously announced, RTI’s management has been implementing
a series of initiatives to reduce complexity, drive operational
excellence, and accelerate growth to position the company for
long-term and sustainable profitability. As part of these
initiatives, RTI has appointed Paul Montague as Head of Human
Resources and Enrico Sangiorgio to lead the company’s international
operations. Mr. Montague brings more than 15 years of global
experience in senior human resources roles to RTI and Mr.
Sangiorgio’s nearly two decades of leadership positions with
European healthcare organizations will be instrumental in growing
RTI’s International platform. The company is also actively
recruiting for its top two R&D positions.
As part of its focus to reduce complexity, RTI recently
completed the previously announced sale of substantially all the
assets of its cardiothoracic closure business to an affiliate of
A&E Medical Corporation for total consideration of up to $60
million in cash. Concurrent with the sale of the business, RTI
entered into a multi-year Contract Manufacturing agreement whereby
RTI will continue to support the cardiothoracic business under
A&E Medical’s ownership through the manufacturing of existing
products and the engineering, development and manufacturing of
potential new products in the future.
RTI used the majority of the proceeds from the sale, net of
transaction fees and anticipated taxes, to reduce its term loan, as
it extended the maturity of its existing credit facilities. The
transaction was made possible by RTI’s success growing its
cardiothoracic closure business by a compounded annual growth rate
of more than 25% over the last five years, through a focused
R&D and disciplined direct channel strategy, and demonstrates
RTI’s proven ability to create value in OEM product lines. The sale
of the cardiothoracic closure business represents an important
action toward RTI’s stated goals to reduce complexity in its
business and devote resources to those businesses, products and
markets with the greatest growth potential.
“Longer-term, our focus will continue to be to: 1) simplify our
business to manage costs, specifically in tissue acquisition and
processing, 2) deepen our investments in our people with a focus on
R&D to accelerate growth and innovation, and 3) ensure a
culture of disciplined execution to achieve sustainable
profitability,” said Mr. Farhat. “The sale of our cardiothoracic
closure business during the quarter was an important first step
toward our effort of enhancing RTI’s platform for operational
excellence. We are committed to further streamlining our business
and evaluating strategic growth opportunities so that we can devote
resources to the areas that align best with our long-term growth
aspiration. With our talented team, dedication to our customers and
innovative products, I am optimistic that RTI is on the right path
to success.”
Second Quarter 2017
RTI worldwide revenues were $72.1 million for the second quarter
of 2017, an increase of 7 percent. Direct revenues were $43.6
million for the second quarter of 2017, an increase of 10 percent
compared to the second quarter of 2016, with double-digit growth
reported in RTI’s spine, surgical specialties and cardiothoracic
direct business segments. Commercial/other revenues were $28.6
million for the second quarter of 2017, an increase of 2 percent
compared to the second quarter of 2016.
Net loss applicable to common shares of $2.6 million in the
second quarter of 2017, or $0.04 per fully diluted common share,
primarily due to a previously disclosed pre-tax charge for
severance-related expenses totaling $3.4 million. As outlined in
the reconciliation tables that follow, excluding these charges,
adjusted net income applicable to common shares was $965,000 and
adjusted net income per fully diluted common share was $0.02.
Adjusted earnings before interest, taxes, depreciation and
amortization (Adjusted EBITDA) were $8.3 million, or 11 percent of
second quarter revenue.
Fiscal 2017 Outlook
The company has developed its guidance based on its ongoing
restructuring and operational improvement program, its current
business profile and existing market conditions.
Within this context, based on second quarter results and the
transition of the cardiothoracic closure business from a direct
business to a commercial business as a result of the sale, RTI
expects full year revenues for 2017 to be between $274 million and
$280 million compared to prior guidance of between $274 million and
$285 million, with direct revenues anticipated to grow low-to-mid
single digits on a percentage basis compared to 2016, while
commercial/other revenues are expected to be relatively flat on a
percentage basis.
As detailed in the reconciliation provided later in this
release, excluding the severance-related expenses in the first half
of 2017, the expected third quarter 2017 gain on the sale of the
cardiothoracic closure business, and including the transition of
the cardiothoracic closure business from a direct business to a
commercial business as a result of the sale, RTI expects adjusted
full year net income per fully diluted common share to be between
$0.04 and $0.08 compared to prior guidance of between $0.05 and
$0.10, based on 60 million fully diluted shares outstanding.
RTI will continue to evaluate its operating platform throughout
the year and will update its top and bottom line guidance as its
actions might warrant.
Conference Call
RTI will host a conference call and simultaneous audio webcast
to discuss its second quarter 2017 results at 8:30 a.m. ET today.
The conference call can be accessed by dialing (877) 383-7419. The
webcast can be accessed through the investor section of RTI’s
website at www.rtix.com. A replay of the conference call will be
available on the RTI website following the call.
About RTI Surgical Inc.
RTI Surgical is a leading global surgical implant company
providing surgeons with safe biologic, metal and synthetic
implants. Committed to delivering a higher standard, RTI’s implants
are used in sports medicine, general surgery, spine, orthopedic,
trauma and cardiothoracic procedures and are distributed in nearly
50 countries. RTI is headquartered in Alachua, Fla., and has four
manufacturing facilities throughout the U.S. and Europe. RTI is
accredited in the U.S. by the American Association of Tissue Banks
and is a member of AdvaMed. For more information, please visit
www.rtix.com.
Forward Looking Statement
This communication contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are based on management’s
current expectations, estimates and projections about our industry,
our management's beliefs and certain assumptions made by our
management. Words such as "anticipates," "expects," "intends,"
"plans," "believes," "seeks," "estimates," variations of such words
and similar expressions are intended to identify such
forward-looking statements. In addition, except for historical
information, any statements made in this communication about
anticipated financial results, growth rates, new product
introductions, future operational improvements and results or
regulatory actions or approvals or changes to agreements with
distributors also are forward-looking statements. These statements
are not guarantees of future performance and are subject to risks
and uncertainties, including the risks described in public filings
with the U.S. Securities and Exchange Commission (SEC). Our actual
results may differ materially from the anticipated results
reflected in these forward-looking statements. Copies of the
company's SEC filings may be obtained by contacting the company or
the SEC or by visiting RTI's website at www.rtix.com or the SEC's
website at www.sec.gov.
RTI SURGICAL, INC. AND SUBSIDIARIES Condensed
Consolidated Statements of Operations (Unaudited, in
thousands, except share and per share data)
For the Three Months Ended
For the Six Months Ended
June 30,
June 30,
2017 2016
2017 2016 Revenues $
72,120 $ 67,620 $ 142,059 $ 134,971 Costs of processing and
distribution
35,157
33,671 69,317
64,997 Gross profit
36,963
33,949 72,742
69,974 Expenses:
Marketing, general and administrative 29,496 28,402 59,167 55,954
Research and development 3,740 4,084 7,428 8,245 Severance charges
3,400 711 7,803 711 Restructuring charges - 1,107 - 1,107 Contested
proxy expenses
-
2,372 -
2,680 Total operating expenses
36,636 36,676
74,398 68,697
Operating income (loss)
327
(2,727 ) (1,656
) 1,277 Total other expense
- net
(990 )
(424 ) (1,789
) (738 ) (Loss)
income before income tax (provision) benefit (663 ) (3,151 ) (3,445
) 539 Income tax (provision) benefit
(1,026
) 859
(116 ) (430
) Net (loss) income
(1,689
) (2,292 )
(3,561 ) 109
Convertible preferred dividend
(924
) (870 )
(1,834 ) (1,728
) Net loss applicable to common shares
$
(2,613 ) $
(3,162 ) $
(5,395 ) $
(1,619 ) Net loss per common share
- basic
$ (0.04 )
$ (0.05 ) $
(0.09 ) $ (0.03
) Net loss per common share - diluted
$
(0.04 ) $ (0.05
) $ (0.09 )
$ (0.03 ) Weighted average
shares outstanding - basic
58,935,786
58,215,477
58,715,791 58,065,185
Weighted average shares outstanding - diluted
58,935,786 58,215,477
58,715,791
58,065,185 RTI SURGICAL, INC.
AND SUBSIDIARIES Reconciliation of Net (Loss) Income
Applicable to Commons Shares to Adjusted EBITDA (Unaudited,
in thousands)
For the Three Months For the Six
Months Ended June 30, Ended June 30, 2017
2016 2017 2016 Net (loss) income $ (2,613 ) $
(3,162 ) $ (5,395 ) $ (1,619 ) Interest expense, net 915 386 1,734
746 Provision for income taxes 1,026 (859 ) 116 430 Depreciation
2,652 3,454 5,324 6,836 Amortization of intangible assets
909 930
1,805 1,858 EBITDA
2,889 749 3,584 8,251
Reconciling items for Adjusted EBITDA
Preferred dividend 924 870 1,834 1,728 Non-cash stock based
compensation 974 600 1,808 1,100 Foreign exchange gain 75 38 55 (8
)
Other reconciling items(1)
Severance charges excluding stock based compensation 3,400 711
7,470 711 Restructuring charges - 1,107 - 1,107 Contested proxy
expenses
- 2,372
- 2,680
Adjusted EBITDA
$ 8,262
$ 6,447 $
14,751 $ 15,569
Adjusted EBITDA as a percent of revenues
11
%
10
%
10
%
12
%
(1)See explanations in Use of Non-GAAP Financial
Measures section later in this release.
RTI
SURGICAL, INC. AND SUBSIDIARIES Reconciliation of Net Loss
Applicable to Common Shares and Net Loss Per Diluted Share to
Adjusted Net Income (Loss) Applicable to Common Shares and
Adjusted Net Income (Loss) Per Diluted Share (Unaudited, in
thousands, except per share data)
For the Three Months Ended June 30, 2017 June 30,
2016
Net
Income
Applicable to
Common Shares
Amount
per Diluted
Share
Net
Income
Applicable to
Common Shares
Amount
per Diluted
Share
As reported $ (2,613 ) $ (0.04 ) $ (3,162 ) $ (0.05 ) Severance
charges 3,400 0.06 711 0.01 Restructuring charges - - 1,107 0.02
Contested proxy expenses - - 2,372 0.04 Tax effect on adjustments
178 0.00
(1,237 ) (0.02
) Adjusted *
$ 965
$ 0.02 $
(209 ) $ (0.00
) For the Six Months Ended June 30,
2017 June 30, 2016
Net
Income
Applicable to
Common Shares
Amount
per Diluted
Share
Net
Income
Applicable to
Common Shares
Amount
per Diluted
Share
As reported $ (5,395 ) $ (0.09 ) $ (1,619 ) $ (0.03 ) Severance
charges 7,803 0.13 711 0.01 Restructuring charges - - 1,107 0.02
Contested proxy expenses - - 2,680 0.05 Tax effect on adjustments
(1,304 ) (0.02
) (1,355 )
(0.02 ) Adjusted *
$
1,104 $ 0.02
$ 1,524 $
0.03 * See explanations in Use of
Non-GAAP Financial Measures section later in this release. Amount
Per Diluted Share may not foot due to rounding.
Fiscal 2017 Outlook
Full year net income per fully diluted common share is expected
to be in the range of $0.00 to $0.04, based on 60 million fully
diluted shares outstanding. Excluding severance charges taken in
2017, full year net income per fully diluted common share is
expected to be in the range of $0.04 to $0.08.
RTI SURGICAL, INC. AND SUBSIDIARIES Reconciliation
of GAAP Guidance Net Income Per Common Share - Diluted to
Adjusted Non-GAAP Guidance Net Income Per Common Share -
Diluted (Unaudited) Twelve Months
Ended December 31, 2017 $ Amount Per
Common Share - Diluted GAAP Guidance Net Income Per
Common Share - Diluted $ 0.00 - 0.04 Severance charges, net of tax
effect
0.04 Adjusted Non-GAAP Guidance Net Income Per
Common Share - Diluted
$ 0.04 - 0.08
Use of Non-GAAP Financial
Measures
To supplement the Company’s unaudited condensed consolidated
financial statements presented on a GAAP basis, the Company
discloses certain non-GAAP financial measures that exclude certain
amounts, including Adjusted EBITDA, Adjusted Net Income Applicable
to Common Shares and Adjusted Net Income per Common Share -
Diluted. The calculation of the tax effect on the adjustments
between GAAP net (loss) income applicable to common shares and
non-GAAP net income applicable to common shares is based upon our
estimated annual GAAP tax rate, adjusted to account for items
excluded from GAAP net (loss) income applicable to common shares in
calculating Adjusted Net Income Applicable to Common
Shares-Diluted. A reconciliation of the non-GAAP financial measures
to the corresponding GAAP measures is included in the tables listed
above.
The following is an explanation of the adjustments that
management excluded as part of adjusted measures for the three and
six month period ended June 30, 2017 and 2016 as well as the reason
for excluding the individual items:
(1) Severance charges – This adjustment represents charges
relating to the termination of former employees. Management removes
the amount of these costs from our operating results to supplement
a comparison to our past operating performance.
(2) Restructuring charges – This adjustment represents the
closure of our French distribution and tissue procurement office.
Management removes the amount of these costs from our operating
results to supplement a comparison to our past operating
performance.
(3) Contested proxy expenses – This adjustment represent charges
relating to contested proxy expenses. Management removes the amount
of these costs from our operating results to supplement a
comparison to our past operating performance.
Material Limitations Associated with the
Use of Non-GAAP Financial Measures
Adjusted EBITDA, Adjusted Net Income Applicable to Common Shares
and Adjusted Net Income per Common Share - Diluted should not be
considered in isolation, or as a replacement for GAAP measures.
Usefulness of Non-GAAP Financial Measures
to Investors
The Company believes that presenting Adjusted EBITDA, Adjusted
Net Income Applicable to Common Shares and Adjusted Net Income per
Common Share - Diluted in addition to the related GAAP measures
provide investors greater transparency to the information used by
management in its financial decision-making. The Company further
believes that providing this information better enables the
Company’s investors to understand the Company’s overall core
performance and to evaluate the methodology used by management to
assess and measure such performance.
RTI SURGICAL, INC. AND
SUBSIDIARIES Condensed Consolidated Revenues
(Unaudited, in thousands) For the Three
Months Ended For the Six Months Ended June 30,
June 30, 2017 2016 2017 2016
Revenues: Spine $ 19,419 $ 17,645 $ 39,757 $ 34,739 Sports
medicine and orthopedics 12,997 12,562 25,893 25,082 Surgical
specialties 1,456 802 3,236 1,817 Cardiothoracic 3,673 2,905 6,824
5,439 International 6,005 5,663 11,662
11,180 Subtotal direct 43,550 39,577 87,372 78,257 Global
commercial 25,837 24,769 49,418 50,099 Other revenues 2,733
3,274 5,269 6,615 Total revenues $ 72,120 $
67,620 $ 142,059 $ 134,971
RTI SURGICAL,
INC. AND SUBSIDIARIES Condensed Consolidated Balance
Sheets (Unaudited, in thousands) June 30,
December 31, 2017 2016 Assets Cash and
cash equivalents $ 13,675 $ 13,849 Accounts receivable - net 39,099
41,488 Inventories - net 116,773 119,743 Prepaid and other current
assets 6,177 5,213 Assets held for sale
1,750
- Total current assets 177,474
180,293 Property, plant and equipment - net 84,379 83,298
Goodwill 54,887 54,887 Other assets - net
49,854 49,553 Total
assets
$ 366,594 $
368,031 Liabilities and Stockholders'
Equity Accounts payable $ 27,745 $ 26,112 Accrued expenses and
other current liabilities 25,668 26,772 Current portion of
long-term obligations
5,779
6,080 Total current liabilities 59,192 58,964
Deferred revenue 6,176 6,612 Long-term liabilities
75,201 77,523 Total
liabilities 140,569 143,099 Preferred stock, including
accrued dividends 61,941 60,016 Stockholders' equity: Common
stock and additional paid-in capital 417,886 416,570 Accumulated
other comprehensive loss (6,903 ) (8,316 ) Accumulated deficit
(246,899 )
(243,338 ) Total stockholders' equity
164,084 164,916
Total liabilities and stockholders' equity
$
366,594 $ 368,031
RTI SURGICAL, INC. AND
SUBSIDIARIES Condensed Consolidated Statements of Cash
Flows (Unaudited, in thousands) For the Three
Months For the Six Months Ended June 30, Ended
June 30, 2017 2016 2017 2016
Cash flows from operating activities: Net (loss) income $
(1,689 ) $ (2,292 ) $ (3,561 ) $ 109 Adjustments to reconcile net
(loss) income to net cash provided by operating activities:
Depreciation and amortization expense 3,561 4,384 7,129 8,694
Stock-based compensation 974 600 1,808 1,100 Amortization of
deferred revenue (1,186 ) (1,217 ) (2,460 ) (2,434 )
Other items to reconcile to net cash
provided by operating activities
(624 ) 5,311
7,697 5,740
Net cash provided by operating activities
1,036 6,786
10,613 13,209
Cash flows from investing activities: Purchases of property,
plant and equipment (3,877 ) (4,766 ) (7,160 ) (9,403 ) Patent and
acquired intangible asset costs
(1,526
) (195 )
(1,845 ) (1,391
) Net cash used in investing activities
(5,403 ) (4,961
) (9,005 )
(10,794 ) Cash flows from financing
activities: Proceeds from long-term obligations 2,000 4,000
4,000 7,000 Net payments from short-term obligations - (600 ) -
(849 ) Payments on long-term obligations (3,125 ) (4,166 ) (7,375 )
(8,299 ) Other financing activities
1,467
14 1,433
(94 ) Net cash provided by
(used in) financing activities
342
(752 ) (1,942
) (2,242 ) Effect of
exchange rate changes on cash and cash equivalents
102 (47 )
160 (33
) Net (decrease) increase in cash and cash equivalents
(3,923 ) 1,026 (174 ) 140 Cash and cash equivalents, beginning of
period
17,598 11,728
13,849 12,614
Cash and cash equivalents, end of period
$
13,675 $ 12,754
$ 13,675 $
12,754
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170808005451/en/
RTI Surgical Inc.Robert JordheimChief Financial
Officerrjordheim@rtix.comorRoxane Wergin, 386-418-8888Director,
Corporate Communicationsrwergin@rtix.com
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Sep 2023 to Sep 2024